Pharmacokinetics and Bioequivalence of Doxycycline (Providox® and Doxyvet 0-50 S®) Oral Powder Formulations in Chickens
DOI:
https://doi.org/10.3923/ijps.2008.161.164Keywords:
Bioavailability, bioequivalence, chicken, doxycycline, pharmacokineticsAbstract
A bioequivalence and pharmacokinetics profiles of two doxycycline powder formulations (Providox® and Doxyvet 0-50 S®) were compared in 24 healthy chickens following administration of a single oral dose (20 mg/kg bw). Serial blood samples were drawn at 10 points after administration to determine doxycycline concentrations in chicken plasma by HPLC/UV. the pharmacokinetics parameters; area under plasma concentration-time curve (AUC0-24), maximum plasma concentration (Cmax) were determined for both formulations. The average means of AUC0-24 and Cmax for Providox® and Doxyvet 0-50 S® were very close (62.32 ± 3.34 and 57.55 ± 4.66 µg.h/ml and 5.36 ± 0.26 and 5.08 ± 0.25 µg/ml, respectively) with no significant differences based on ANOVA. The 90% confidence intervals of the parameters AUC0-24 and Cmax between two formulations were within the range 80 to 125 % of bioequivalence according to US FDA regulation. The relative bioavailability of Providox® compared to Doxyvet 0-50 S® was 108.24%. Therefore, the Providox® and Doxyvet 0 - 50 S® were considered to be bioequivalent.
Downloads
Published
Issue
Section
License
Copyright (c) 2008 Asian Network for Scientific Information

This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.